Soleno Therapeutics (SLNO) Gains from Sales and Divestitures (2016 - 2026)
Soleno Therapeutics (SLNO) reported Gains from Sales and Divestitures of $84850.0 for Q1 2026, down 89.4% year-over-year from $800500.0 in Q1 2025, and down 90.44% on a QoQ basis from $887124.0 in Q4 2025.
Soleno Therapeutics (SLNO) has 9 years of Gains from Sales and Divestitures data on file, last reported at $84850.0 in Q1 2026.
- Quarterly Gains from Sales and Divestitures fell 89.4% year-over-year to $84850.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84850.0 (down 89.4% YoY) and the FY2025 annual result came in at $887124.0, down 18.49% from the prior year.
- Gains from Sales and Divestitures retreated to $84850.0 in Q1 2026 per SLNO's latest filing, from $887124.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $1.1 million in Q4 2024 and bottomed at $9534.0 in Q1 2023.
- The 5-year median for Gains from Sales and Divestitures is $279757.0 (2022), against an average of $392023.1.
- The widest annual swing landed in 2023, when Gains from Sales and Divestitures plunged 96.59%; it then surged 9869.94% in 2024.
- Tracing SLNO's Gains from Sales and Divestitures over 5 years: stood at $18646.0 in 2022, then surged by 2169.91% to $423248.0 in 2023, then surged by 157.13% to $1.1 million in 2024, then slipped by 18.49% to $887124.0 in 2025, then plunged by 90.44% to $84850.0 in 2026.
- Per Business Quant, the three latest SLNO Gains from Sales and Divestitures figures stand at $84850.0 (Q1 2026), $887124.0 (Q4 2025), and $825607.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,850.00 |
| Mar 31, 2026 | 84,850.00 |
| Dec 31, 2025 | 887,124.00 |
| Dec 31, 2025 | 887,124.00 |
| Sep 30, 2025 | 825,607.00 |
| Sep 30, 2025 | 825,607.00 |
| Jun 30, 2025 | 819,273.00 |
| Jun 30, 2025 | 819,273.00 |
| Mar 31, 2025 | 800,500.00 |
| Mar 31, 2025 | 800,500.00 |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 950,534.00 |
| Sep 30, 2024 | 950,534.00 |
| Jun 30, 2024 | 74,250.00 |
| Jun 30, 2024 | 74,250.00 |
| Mar 31, 2024 | 85,284.00 |
| Mar 31, 2024 | 85,284.00 |
| Dec 31, 2023 | 423,248.00 |
| Dec 31, 2023 | 423,248.00 |
| Sep 30, 2023 | 9,534.00 |
| Sep 30, 2023 | 9,534.00 |
| Jun 30, 2023 | 9,534.00 |
| Jun 30, 2023 | 9,534.00 |
| Mar 31, 2023 | 9,534.00 |
| Mar 31, 2023 | 9,534.00 |
| Dec 31, 2022 | 18,646.00 |
| Dec 31, 2022 | 18,646.00 |
| Sep 30, 2022 | 18,646.00 |
| Sep 30, 2022 | 18,646.00 |
| Jun 30, 2022 | 279,757.00 |
| Jun 30, 2022 | 279,757.00 |
| Mar 31, 2022 | 279,757.00 |
| Mar 31, 2022 | 279,757.00 |
| Dec 31, 2021 | 21,546.00 |
| Dec 31, 2021 | 21,546.00 |
| Sep 30, 2021 | 258,995.00 |
| Sep 30, 2021 | 258,995.00 |
| Jun 30, 2021 | 206,523.00 |
| Jun 30, 2021 | 206,523.00 |
| Mar 31, 2021 | 167,060.00 |
| Mar 31, 2021 | 167,060.00 |
| Dec 31, 2020 | 103,133.00 |
| Dec 31, 2020 | 103,133.00 |
| Sep 30, 2020 | 78,565.00 |
| Sep 30, 2020 | 78,565.00 |
| Jun 30, 2020 | 45,218.00 |
| Jun 30, 2020 | 45,218.00 |
| Mar 31, 2020 | 28,757.00 |
| Mar 31, 2020 | 28,757.00 |
| Dec 31, 2019 | 61,218.00 |
| Dec 31, 2019 | 61,218.00 |
| Jun 30, 2016 | 5,499.00 |
| Jun 30, 2016 | 5,499.00 |